Abstract
Apoptosis is a morphologically distinct form of programmed cell death that plays a major role in cancer treatments. This cellular suicide program is known to be regulated by many different signals from both intracellular and extracellular stimuli. Here we report that p53 suppressed expression of the cellular FLICE-inhibitory protein (FLIP) that potentially blocks apoptotic signaling in human colon cancer cell lines expressing mutated and wild-type p53. In contrast, the expression of the death receptor KILLER/DR5 (TRAIL-R2) had no effect on FLIP expression, although exogenous p53 is known to induce KILLER/DR5 expression. In line with these observations, FLIP-negative cancer cells were sensitive to both p53- and KILLER/DR5-mediated apoptosis, whereas cells containing high levels of FLIP underwent apoptotic cell death when triggered by ectopic p53 expression but not by KILLER/DR5 expression. Treating the cells with a specific inhibitor of the proteasome inhibited the decrease of FLIP by p53, suggesting that p53 enhances the degradation of FLIP via a ubiquitin-proteasome pathway. Thus, the data indicate that p53-mediated downregulation of FLIP may explain the potent sensitization of human cancer cells to the apoptotic suicide program induced by wild-type p53 gene transfer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ashkenazi A, Dixit VM . 1998 Science 281: 1305–1308
Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P . 1998 Science 282: 290–293
Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM . 1995 Cell 81: 505–512
Fukazawa T, Fujiwara T, Morimoto Y, Shao J, Nishizaki M, Kadowaki Y, Hizuta A, Owen-Schaub LB, Roth JA, Tanaka N . 1999 Oncogene 18: 2189–2199
Honda R, Yasuda H . 1999 EMBO J. 18: 22–27
Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J . 1997 Nature 388: 190–195
Kagawa S, Fujiwara T, Hizuta A, Yasuda T, Zhang WW, Roth JA, Tanaka N . 1997 Oncogene 15: 1903–1909
Kanegae Y, Takamori K, Sato Y, Lee G, Nakai M, Saito I . 1996 Gene 181: 207–212
Kataoka T, Schroter M, Hahne M, Schneider P, Irmler M, Thome M, Froelich CJ, Tschopp J . 1998 J. Immunol. 161: 3936–3942
Levine AJ . 1997 Cell 88: 323–331
Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, Peter ME . 1997 EMBO J. 16: 2749–2804
Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM . 1996 Cell 85: 817–827
Niwa H, Yamamura K, Miyazaki J . 1991 Gene 108: 193–200
Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky R . 1995 Mol. Cell. Biol. 15: 3032–3040
Sata M, Walsh K . 1998 J. Biol. Chem. 273: 33103–33106
Scaffidi C, Schmitz I, Krammer PH, Peter ME . 1999 J. Biol. Chem. 274: 1541–1548
Scheffner M, Nuber U, Huibregtse JM . 1995 Nature 373: 81–83
Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J . 1997 Immunity 7: 831–836
Shao J, Fujiwara T, Kadowaki Y, Fukazawa T, Waku T, Itoshima T, Yamatsuji T, Nishozaki M, Roth JA, Tanaka N . 2000 Oncogene 19: 726–736
Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace Jr AJ, el-Deiry WS . 1998 Cancer Res. 58: 1593–1598
Shkedy D, Gonen H, Bercovich B, Ciechanover A . 1994 FEBS Lett. 348: 126–130
Wu GS, el-Diery WS . 1997 Nat. Genet. 17: 141–143
Wu GS, Burns TF, Zhan Y, Alnemri ES, el-Deiry WS . 1999 Cancer Res. 59: 2770–2775
Acknowledgements
We thank Dr Hideo Yagita for providing KILLER/DR5 cDNA; Dr Izumu Saito for providing pCANLNL5 and AxCANCre; Dr Jun-ichi Miyazaki for providing the CAG promoter; and Monica Contreas for preparing the manuscript. This work was supported in part by grants from the Ministry of Education, Science, and Culture, Japan; and by grants from the Ministry of Health and Welfare, Japan (Health Sciences Research Grants [Research on Human Genome and Gene Therapy]).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fukazawa, T., Fujiwara, T., Uno, F. et al. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene 20, 5225–5231 (2001). https://doi.org/10.1038/sj.onc.1204673
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204673
Keywords
This article is cited by
-
Beyond Death: Unmasking the Intricacies of Apoptosis Escape
Molecular Diagnosis & Therapy (2024)
-
PP6 negatively modulates LUBAC-mediated M1-ubiquitination of RIPK1 and c-FLIPL to promote TNFα-mediated cell death
Cell Death & Disease (2022)
-
cFLIP downregulation is an early event required for endoplasmic reticulum stress-induced apoptosis in tumor cells
Cell Death & Disease (2022)
-
Glutamine metabolism regulates FLIP expression and sensitivity to TRAIL in triple-negative breast cancer cells
Cell Death & Disease (2018)
-
Glycogen synthase kinase-3β inhibition promotes lysosome-dependent degradation of c-FLIPL in hepatocellular carcinoma
Cell Death & Disease (2018)